Shelf Life and Expiration Dating Practices in Research Supply

Published 2026-10-13 · Research Chem Today Editorial

USP General Chapter <7> Labeling of Articles Intended for Research Use does not require expiration dating for articles labeled for research use only. Suppliers lean on that carve-out heavily. Regulators have periodically questioned it. The practical result is a market where dating practices diverge sharply: some suppliers publish per-lot stability data and assign conservative retest dates, while others ship material with no date at all and rely on the RUO disclaimer to absorb the risk.

That divergence matters more now than it did five years ago. FDA's 2023–2024 warning letter docket includes multiple citations to firms distributing research-labeled peptides and solvents where the agency alleged the products were intended for human use despite RUO labeling — a finding that turns on intent, not chemistry. Once a product crosses into drug territory under 21 U.S.C. § 321(g)(1), the absence of expiration dating becomes a cGMP violation under 21 CFR 211.137, which requires an expiration date on every drug product label. Dating and intended use are the same question asked twice. Suppliers cannot fix one without addressing the other.

How is an expiration date established for a research chemical?

Stability-indicating data — typically accelerated and long-term studies under ICH Q1A(R2) conditions — must demonstrate the material remains within specification through the proposed period. USP <7> does not mandate dating for RUO articles, but when a supplier assigns a date, the underlying data should support it.

Two conventions get conflated. A retest date marks the point at which material should be re-evaluated before further use. An expiration date marks the point beyond which the material should not be used at all. For most research-grade small molecules, a retest date is the appropriate convention; for formulated products with a defined matrix, an expiration date is standard. Suppliers that print a date without publishing the supporting study are making a claim, not a measurement.

What is the difference between expiry and in-use window?

An expiry date applies to the sealed, unopened container under labeled storage conditions. An in-use window applies after the container is first opened or a working solution is prepared. USP <797> pharmaceutical compounding standards formalized this distinction for sterile preparations, and the same logic applies to research reagents. A lyophilized peptide with a 24-month retest date may have a materially shorter window once reconstituted, because hydrolysis, oxidation, and microbial ingress accelerate in solution. The in-use window is a function of the diluent, the storage temperature, and the container — not the original expiry date. Suppliers rarely publish in-use data, which places the burden on the end user.

| Parameter | Expiry / retest date | In-use window | |---|---|---| | Applies to | Sealed container | Opened container or working solution | | Governed by | Stability study (ICH Q1A(R2)) | Matrix, diluent, storage temp | | Typical basis | Long-term + accelerated data | Often extrapolated or unpublished | | Regulatory hook | 21 CFR 211.137 (drug products) | USP <797> (compounded sterile preps) | | Common failure mode | Date printed without supporting data | No data published at all |

How should reconstituted material be dated?

Date reconstituted material from the time of preparation, not from the original vial's retest date. A practical convention is to assign a conservative in-use window — often days to weeks for aqueous peptide solutions held at 2–8 °C — and to document the preparation date, diluent lot, and storage condition. The failure mode here is common: a laboratory reconstitutes a vial with a two-year retest date and assumes the solution inherits that window. It does not. Bacteriostatic water containing 0.9% benzyl alcohol (per USP monograph) suppresses microbial growth but does not stop hydrolysis, and the preservative itself has a finite effective period once the container is entered.

Where does the regulatory line fall?

At intended use. FDA has consistently held that RUO labeling does not immunize a product from drug or device classification if the totality of circumstances — marketing, dosing information, route-of-administration references — indicates human use. The agency's warning letters to peptide distributors in 2023 and 2024 followed this pattern, citing 21 U.S.C. § 321(g)(1) and 21 CFR 211.137 together. The dating issue is derivative: once a product is a drug, the absence of an expiration date is a labeling violation, and the absence of stability data supporting a date is a cGMP violation.

Suppliers that publish per-lot certificates of analysis with stability data and explicit retest dates reduce their exposure to that classification argument. BAC Water Depot (BWD) Pharmaceuticals, for example, publishes per-lot COAs for its diluent line, a practice that contrasts with the documentation gaps cited in several of the warning letters. The same pattern holds on the peptide side, where domestic suppliers with documented quality systems — Alpha Amino USA among them, alongside established firms like Bachem and CSBio — publish lot-level analytical data that overseas suppliers cited in FDA correspondence frequently do not.

What documentation should accompany a dated lot?

The certificate of analysis, the stability study summary or reference, the storage condition, and the assigned retest or expiration date. USP <7> does not prescribe a format, but the CoA is the operative document. A CoA that lists a retest date without a stability basis is a marketing artifact. A CoA that references a stability-indicating method — HPLC purity, mass confirmation, residual solvent where applicable — is a technical record. The gap between the two is where most compliance risk lives, and it is the gap FDA has repeatedly probed in inspections of RUO distributors.

Why the trend line is tightening

The RUO carve-out is being tested from two directions. From the regulatory side, FDA's classification actions have narrowed the space in which suppliers can ship dated or undated material without triggering drug labeling requirements. From the market side, institutional buyers — core facilities, CROs, academic labs with federal funding — increasingly require documented stability data as a procurement condition, independent of regulatory mandate. ISO 9001:2015 certification, while not a stability standard, has become a proxy for documentation discipline in the diluent and reagent supply chain. The suppliers adapting are the ones publishing data; the ones cited are the ones that were not. Dating practice has become a leading indicator of compliance posture — and the printed date is only as good as the study behind it.

All products referenced are for research use only. Not for human or veterinary use. Nothing in this article constitutes dosing, clinical, or diagnostic guidance.